National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Adverse Drug Events (ADE) (1)
- Adverse Events (1)
- Antibiotics (2)
- Cancer (1)
- Cancer: Breast Cancer (1)
- Cardiovascular Conditions (2)
- Case Study (1)
- Disparities (1)
- Healthcare-Associated Infections (HAIs) (1)
- Injuries and Wounds (1)
- (-) Medication (6)
- Patient Safety (1)
- Practice Patterns (1)
- (-) Prevention (6)
- (-) Risk (6)
- Surgery (1)
- U.S. Preventive Services Task Force (USPSTF) (2)
- Women (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 6 of 6 Research Studies DisplayedFan T, Fakolade A
AHRQ Author: Fan T
Medication use to reduce risk of breast cancer.
In this case study, a 40-year-old woman comes to her doctor’s office for a routine gynecologic visit. She is not taking any medications and is generally healthy. She is sexually active, and her last menstrual period started 10 days ago. She states that her mother was diagnosed with bilateral breast cancer at 49 years of age and that she would like to discuss her options for reducing the risk of breast cancer. Three questions are posed about risk-reducing medications.
AHRQ-authored
Citation: Fan T, Fakolade A .
Medication use to reduce risk of breast cancer.
Am Fam Physician 2020 Mar 15;101(6):373-74..
Keywords: U.S. Preventive Services Task Force (USPSTF), Cancer: Breast Cancer, Cancer, Medication, Risk, Prevention, Case Study, Women
Schmajuk G, Jafri K, Evans M
Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
This study examined the use of prophylactic drugs used to prevent Pneumocystis jirovecii pneumonia (PJP), a rare condition sometimes caused by use of high risk immunosuppressants. This disease has a high rate of mortality. The study authors followed 316 patients for about 1-2 years who had high risk conditions such as vasculitis, myositis, or systemic lupus erythematosus. Overall, 39% of patients received prophylactic antibiotics. However, at least 25% of the patients with the highest risk conditions (vasculitis) or highest risk for immunosuppressants did not receive PJP prophylaxis. During the study period, no cases of PJP ever occurred among any of the study group.
AHRQ-funded; HS023558; HS024412.
Citation: Schmajuk G, Jafri K, Evans M .
Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs.
Semin Arthritis Rheum 2019 Jun;48(6):1087-92. doi: 10.1016/j.semarthrit.2018.10.018..
Keywords: Antibiotics, Medication, Prevention, Risk
Olsen MA, Nickel KB, Fraser VJ
Prevalence and predictors of postdischarge antibiotic use following mastectomy.
This study determined utilization, predictors, and outcomes of postdischarge prophylactic antibiotics after mastectomy with or without immediate breast reconstruction. The study conclude that prophylactic postdischarge antibiotics are commonly prescribed after mastectomy; immediate reconstruction is the strongest predictor. The authors recommended stewardship efforts in this population to limit continuation of prophylactic antibiotics after discharge are needed to limit antimicrobial resistance.
AHRQ-funded; HS019455.
Citation: Olsen MA, Nickel KB, Fraser VJ .
Prevalence and predictors of postdischarge antibiotic use following mastectomy.
Infect Control Hosp Epidemiol 2017 Sep;38(9):1048-54. doi: 10.1017/ice.2017.128.
.
.
Keywords: Antibiotics, Healthcare-Associated Infections (HAIs), Medication, Patient Safety, Surgery, Injuries and Wounds, Prevention, Adverse Events, Risk
Naidech AM, Toledo P, Prabhakaran S
Disparities in the use of seizure medications after intracerebral hemorrhage.
The researchers investigated potential disparities in the use of prophylactic seizure medications in patients with intracerebral hemorrhage. They concluded that although multicenter electronic health record data showed apparent racial/ethnic disparities in the use of prophylactic seizure medications, a more complete single-center cohort found the apparent disparity to be confounded by the clinical factors of hypertension and hematoma location.
AHRQ-funded; HS023437; HS000078.
Citation: Naidech AM, Toledo P, Prabhakaran S .
Disparities in the use of seizure medications after intracerebral hemorrhage.
Stroke 2017 Mar;48(3):802-04. doi: 10.1161/strokeaha.116.015779.
.
.
Keywords: Disparities, Medication, Prevention, Adverse Drug Events (ADE), Risk
Guirguis-Blake JM, Evans CV, Senger CA
Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force.
This is an update of a systematic review about the benefits of aspirin for the primary prevention of cardiovascular events in adults aged 40 years or older and to evaluate effect modification in subpopulations. It concluded that the beneficial effect of aspirin for the primary prevention of CVD is modest and also occurs at doses of 100 mg or less per day. Older adults seem to achieve a greater relative MI benefit.
AHRQ-funded; 290201200015.
Citation: Guirguis-Blake JM, Evans CV, Senger CA .
Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force.
Ann Intern Med 2016 Jun 21;164(12):804-13. doi: 10.7326/m15-2113.
.
.
Keywords: U.S. Preventive Services Task Force (USPSTF), Cardiovascular Conditions, Medication, Risk, Prevention
Goldsweig AM, Reid KJ, Gosch K
Contemporary use of dual antiplatelet therapy for preventing cardiovascular events.
The authors examined dual antiplatelet therapy (DAPT) use in contemporary clinical practice after publication of the results of the landmark randomized clinical trial CHARISMA. They found that use of DAPT is modest in patients with established cardiovascular disease, for whom the CHARISMA trial suggested decreased major adverse cardiovascular events (MACEs), and prescription rates have remained stable over time; use of DAPT in patients with multiple risk factors only, for whom CHARISMA suggested that DAPT may lead to increased MACEs, was low and decreased over time.
AHRQ-funded; HS018781.
Citation: Goldsweig AM, Reid KJ, Gosch K .
Contemporary use of dual antiplatelet therapy for preventing cardiovascular events.
Am J Manag Care 2014 Aug;20(8):659-65.
.
.
Keywords: Cardiovascular Conditions, Medication, Prevention, Practice Patterns, Risk